About Repros Therapeutics
Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: RPRX
- CUSIP: 76028H20
- Previous Close: $1.21
- 50 Day Moving Average: $1.27
- 200 Day Moving Average: $1.71
- 52-Week Range: $0.81 - $3.48
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.95
- P/E Growth: -0.06
- Market Cap: $30.76M
- Outstanding Shares: 25,425,000
- Beta: -0.82
- Net Margins: -39,128.00%
- Return on Equity: -151.63%
- Return on Assets: -127.79%
Companies Related to Repros Therapeutics:
- Current Ratio: 4.63%
- Quick Ratio: 4.63%
What is Repros Therapeutics' stock symbol?
Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX."
Where is Repros Therapeutics' stock going? Where will Repros Therapeutics' stock price be in 2017?
1 equities research analysts have issued 12 month target prices for Repros Therapeutics' stock. Their forecasts range from $1.50 to $1.50. On average, they anticipate Repros Therapeutics' stock price to reach $1.50 in the next year.
When will Repros Therapeutics announce their earnings?
Repros Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns Repros Therapeutics stock?
Repros Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (6.58%) and Renaissance Technologies LLC (2.82%).
Who bought Repros Therapeutics stock? Who is buying Repros Therapeutics stock?
Repros Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
How do I buy Repros Therapeutics stock?
Shares of Repros Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Repros Therapeutics stock cost?
One share of Repros Therapeutics stock can currently be purchased for approximately $1.21.